Evidence map›Paper›PMID 41123812›Full record

ReviewBreast cancer (Tokyo, Japan)2026

Immune checkpoint inhibition in breast cancer: targeting PD-1/PD-L1 pathway for therapeutic advances.

Yunjin Shin, Kibeom Shin, Sihyeon Lee, Yena Son, Inmoo Rhee

Abstract readReview
PubMed Publisher
In one paragraph

Review in Breast cancer (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Yunjin ShinDepartment of Biotechnology and Bioscience, Sejong University, Seoul, Korea.
Kibeom Shin *Department of Biotechnology and Bioscience, Sejong University, Seoul, Korea.
Sihyeon Lee *Department of Biotechnology and Bioscience, Sejong University, Seoul, Korea.
Yena Son *Department of Biotechnology and Bioscience, Sejong University, Seoul, Korea.
Inmoo RheeDepartment of Biotechnology and Bioscience, Sejong University, Seoul, Korea. nature@sejong.ac.kr.ORCID http://orcid.org/0000-0001-5272-712X

Funding

National Research Foundation of Korea NRF-2021R1F1A1063321
6 · The paper itself

Abstract

Breast cancer (BC) is among the most prevalent and immunogenic malignancies in women, characterized by rapid proliferation and significant immune cell infiltration into the tumor microenvironment (TME). The programmed cell death protein 1 (PD-1) and its ligand PD-L1 form a critical immune checkpoint axis exploited by tumors to evade immune detection. Targeting this pathway with immune checkpoint inhibitors (ICIs) has shown clinical promise, particularly in triple-negative breast cancer (TNBC). The IMpassion130 trial demonstrated that atezolizumab plus nab-paclitaxel extended progression-free survival (PFS) to 7.5 months compared to 5.0 months with chemotherapy alone. Similarly, the KEYNOTE-522 trial reported a 64.8% pathological complete response (pCR) rate with pembrolizumab-chemotherapy versus 51.2% in the control group. This review summarizes the PD-1/PD-L1 pathway and highlights the therapeutic impact, clinical advances, and future potential of ICIs in BC treatment.

Indexed as

B7-H1 AntigenBreast NeoplasmsImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorTriple Negative Breast NeoplasmsAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansMolecular Targeted TherapySignal TransductionTumor MicroenvironmentAntibodies, Monoclonal, HumanizedatezolizumabB7-H1 AntigenCD274 protein, humanImmune Checkpoint InhibitorsPDCD1 protein, humanProgrammed Cell Death 1 ReceptorBreast cancerImmune checkpoint inhibitor (ICI)Programmed cell death 1 (PD-1)Programmed cell death ligand1 (PD-L1)Triple-negative breast cancer (TNBC)

Identifiers

PMID41123812

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.